Protein Targets and the Roles of Natural Compounds in the Treatment and Management of Hypercholesterolemia: A Comprehensive Review
Article Sidebar
Main Article Content
Abstract
Hypercholesterolemia, a condition characterized by elevated cholesterol levels, has been identified as a major risk factor for cardiovascular disease, which is recognized as the leading cause of mortality on a global scale. Whereas statins remain the cornerstone of pharmacological treatment for hypercholesterolemia, their long-term use is often limited by side effects such as myopathy and hepatotoxicity. Natural bioactive compounds derived from medicinal plants and foods have emerged as promising alternatives for treating hypercholesterolemia due to their multi-target mechanisms, reduced side effects, and wide availability. These compounds, including polyphenols, flavonoids, terpenoids, and plant sterols, have demonstrated efficacy in regulating major cholesterol metabolic pathways, such as reducing intestinal cholesterol absorption, inhibiting cholesterol synthesis, regulating transcription factors, and increasing cholesterol excretion. This review discusses the molecular mechanisms through which previous natural compounds regulate cholesterol homeostasis, focusing on their interactions with proteins such as HMGCR, NPC1L1, PCSK9, and the transcription factor SREBP-2.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Transfer Statement
The copyright of this article is transferred to Current Applied Science and Technology journal with effect if and when the article is accepted for publication. The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, electronic form (offline, online) or any other reproductions of similar nature.
The author warrants that this contribution is original and that he/she has full power to make this grant. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors.
Here is the link for download: Copyright transfer form.pdf
References
Aldalou, A. R. (2021). Hypolipidemic effects of curcumin, cinnamon, vitamin C and simvastatin in domestic rabbits. GSC Biological and Pharmaceutical Sciences, 15(1), 119-131. https://doi.org/10.30574/gscbps.2021.15.1.0103
Alloubani, A., Nimer, R., & Samara, R. (2021). Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review. Current Cardiology Reviews, 17(6), Article e0511211890015. https://doi.org/10.2174/1573403X16999201210200342
Bardolia, C., Amin, N. S., & Turgeon, J. (2021). Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol. Frontiers in Cardiovascular Medicine, 8, Article 789931. https://doi.org/10.3389/fcvm.2021.789931
Baskaran, G., Salvamani, S., Ahmad, S. A., Shaharuddin, N. A., Pattiram, P. D., & Shukor, M. Y. (2015). HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia. Drug Design, Development and Therapy, 9, 509-517. https://doi.org/10.2147/DDDT.S75056
Bondemark, L., & Ruf, S. (2015). Randomized controlled trial: the gold standard or an unobtainable fallacy? European Journal of Orthodontics, 37(5), 457-461. https://doi.org/10.1093/ejo/cjv046
Boudoulas, K. D., Triposkiadis, F., Geleris, P., & Boudoulas, H. (2016). Coronary atherosclerosis: pathophysiologic basis for diagnosis and management. Progress in Cardiovascular Diseases, 58(6), 676-692. https://doi.org/10.1016/j.pcad.2016.04.003
Carson, J. A. S., Lichtenstein, A. H., Anderson, C. A. M., Appel, L. J., Kris-Etherton, P. M., Meyer, K. A., Petersen, K., Polonsky, T., & Van Horn, L. (2020). Dietary cholesterol and cardiovascular risk: a science advisory from the American Heart Association. Circulation, 141(3), e39-e53. https://doi.org/10.1161/CIR.0000000000000743
Cerqueira, N. M., Oliveira, E. F., Gesto, D. S., Santos-Martins, D., Moreira, C., Moorthy, H. N., Ramos, M. J., & Fernandes, P. A. (2016).
Cholesterol biosynthesis: a mechanistic overview. Biochemistry, 55(39), 5483-5506. https://doi.org/10.1021/acs.biochem.6b00342
Cesaro, A., Bianconi, V., Gragnano, F., Moscarella, E., Fimiani, F., Monda, E., Scudiero, O., Limongelli, G., Pirro, M., & Calabrò, P. (2020). Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition. Biofactors, 46(3), 367-380. https://doi.org/10.1002/biof.1619
Chaachouay, N. (2025). Synergy, additive effects, and antagonism of drugs with plant bioactive compounds. Drugs and Drug Candidates, 4(1), Article 4. https://doi.org/10.3390/ddc4010004
Chen, L., Cao, H., Huang, Q., Xiao, J., & Teng, H. (2022). Absorption, metabolism and bioavailability of flavonoids: A review. Critical Reviews in Food Science and Nutrition, 62(28), 7730-7742. https://doi.org/10.1080/10408398.2021.1917508
DiNicolantonio, J. J., Lucan, S. C., & O'Keefe, J. H. (2016). The evidence for saturated fat and for sugar related to coronary heart disease. Progress in Cardiovascular Diseases, 58(5), 464-472. https://doi.org/10.1016/j.pcad.2015.11.006
Feng, J., Xu, R., Dou, Z., Hao, Y., Xu, R., Khoso, M. A., Shi, Y., Liu, L., Sun, H., Chen, C., Li, X., Liu, H., Han, W., Cheng, M., Tang, P., Li, J., Zhang, Y., & Liu, X. (2025). Tetrahydroberberrubine improves hyperlipidemia by activating the AMPK / SREBP2 / PCSK9 / LDL receptor signaling pathway. European Journal of Pharmacology, 989, Article 177228. https://doi.org/10.1016/j.ejphar.2024.177228
Ferrari, I. V. (2024). Unraveling the potential of hypericin: A novel approach to targeting PCSK9 mutations in cholesterol management. bioRxiv, https://doi.org/10.1101/2024.10.06.616901
Fitzgerald, G., & Kiernan, T. (2018). PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Expert Review of Cardiovascular Therapy, 16(8), 567-578. https://doi.org/10.1080/14779072.2018.1497975
Gesto, D. S., Pereira, C. M. S., Cerqueira, N. M. F. S., & Sousa, S. F. (2020). An atomic-level perspective of HMG-CoA-reductase: The target enzyme to treat hypercholesterolemia. Molecules, 25(17), Article 3891. https://doi.org/10.3390/molecules25173891
Ghosh, D., & Mukherjee, P. K. (2019). Natural medicines: clinical efficacy, safety and quality. CRC Press. https://doi.org/10.1201/9781315187853
Gianazza, E., Brioschi, M., Iezzi, A., Paglia, G., & Banfi, C. (2023). Pharmacometabolomics for the study of lipid-lowering therapies: opportunities and challenges. International Journal of Molecular Sciences, 24(4), Article 3291. https://doi.org/10.3390/ijms24043291
Grande, F., Occhiuzzi, M. A., Perri, M. R., Ioele, G., Rizzuti, B., Statti, G., & Garofalo, A. (2021). Polyphenols from Citrus Tacle ® extract endowed with HMGCR inhibitory activity: An antihypercholesterolemia natural remedy. Molecules, 26(18), Article 5718. https://doi.org/10.3390/molecules26185718
Hashemi, M., Hoshyar, R., Ande, S. R., Chen, Q. M., Solomon, C., Zuse, A., & Naderi, M. (2017). Mevalonate cascade and its regulation in cholesterol metabolism in different tissues in health and disease. Current Molecular Pharmacology, 10(1), 13-26. https://doi.org/10.2174/1874467209666160112123746
Hunter, P. M., & Hegele, R. A. (2017). Functional foods and dietary supplements for the management of dyslipidaemia. Nature Reviews Endocrinology, 13(5), 278-288. https://doi.org/10.1038/nrendo.2016.210
Ibrahim, A., Shafie, N. H., Mohd Esa, N., Shafie, S. R., Bahari, H., & Abdullah, M. A. (2020). Mikania micrantha extract inhibits HMG-CoA reductase and ACAT2 and ameliorates hypercholesterolemia and lipid peroxidation in high cholesterol-fed rats. Nutrients, 12(10), Article 3077. https://doi.org/10.3390/nu12103077
Iqbal, J., Al Qarni, A., & Hawwari, A. (2017a). Regulation of intestinal cholesterol absorption: a disease perspective. Advances in Biological Chemistry, 7(1), 60-75. https://doi.org/10.4236/abc.2017.71004
Iqbal, D., Khan, A., Ansari, I. A., & Khan, M. S. (2017b). Investigating the role of novel bioactive compound from Ficus virens Ait on cigarette smoke induced oxidative stress and hyperlipidemia in rats. Iranian Journal of Pharmaceutical Research, 16(3), 1089-1103.
Islam, S. U., Ahmed, M. B., Ahsan, H., & Lee, Y.-S. (2021). Recent molecular mechanisms and beneficial effects of phytochemicals and plant-based whole foods in reducing LDL-C and preventing cardiovascular disease. Antioxidants, 10(5), Article 784. https://doi.org/10.3390/antiox10050784
Jayaraman, S., Roy, A., Vengadassalapathy, S., Sekar, R., Veeraraghavan, V. P., Rajagopal, P., Rengasamy, G., Mukherjee, R., Sekar, D., & Manjunathan, R. (2021). An overview on the therapeutic function of foods enriched with plant sterols in diabetes management. Antioxidants, 10(12), Article 1903. https://doi.org/10.3390/antiox10121903
Kikuchi, T., Orihara, K., Oikawa, F., Han, S., Kuba, M., Okuda, K., Satoh, A., Osaki, Y., Takeuchi, Y., Aita, Y., Matsuzaka, T., Iwasaki, H., Yatoh, S., Sekiya, M., Yahagi, N., Suzuki, H., Sone, H., & Nakagawa, Y. (2016). Intestinal CREBH overexpression prevents high- cholesterol diet-induced hypercholesterolemia by reducing Npc1l1 expression. Molecular Metabolism, 5(11), 1092-1102. https://doi.org/10.1016/j.molmet.2016.09.004
Kim, H., Lee, J., Chung, M., Hong, S., Ho, J., Lee, S., Wook, S., Choi, H., & Hwang, J. (2020). Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition. Pharmacological Research, 161, Article 105205. https://doi.org/10.1016/j.phrs.2020.105205
Kobayashi, S. (2019). The effect of polyphenols on hypercholesterolemia through inhibiting the transport and expression of Niemann - Pick C1-Like 1. International Journal of Molecular Sciences, 20(19), Article 4939. https://doi.org/10.3390/ijms20194939
Kou, Y., Geng, F., & Guo, D. (2022). Lipid metabolism in glioblastoma: from de novo synthesis to storage. Biomedicines, 10(8), Article 1943. https://doi.org/10.3390/biomedicines10081943
Kumar, R., Chhillar, N., Gupta, D. S., Kaur, G., Singhal, S., & Chauhan, T. (2024). Cholesterol homeostasis, mechanisms of molecular pathways, and cardiac health: a current outlook. Current Problems in Cardiology, 49(1), Article 102081. https://doi.org/10.1016/j.cpcardiol.2023.102081
Lammi, C., Zanoni, C., Calabresi, L., & Arnoldi, A. (2016). Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells. Journal of Functional Foods, 23, 230-240. https://doi.org/10.1016/j.jff.2016.02.042
Lammi, C., Zanoni, C., Scigliuolo, G. M., D'Amato, A., & Arnoldi, A. (2014). Lupin peptides lower low-density lipoprotein (LDL) cholesterol through an up-regulation of the LDL receptor/sterol regulatory element binding protein 2 (SREBP2) pathway at HepG2 cell line. Journal of Agricultural and Food Chemistry, 62(29), 7151-7159. https://doi.org/10.1021/jf500795b
Li, N., Li, X., Ding, Y., Liu, X., Diggle, K., Kisseleva, T., & Brenner, D. A. (2023). SREBP regulation of lipid metabolism in liver disease, and therapeutic strategies. Biomedicines, 11(12), Article 3280. https://doi.org/10.3390/biomedicines11123280
Li, Y., Song, Y., Zhao, M., Guo, Y., Yu, C., Chen, W., Shao, S., Xu, C., Zhou, X., Zhao, L.,
Zhang, Z., Bo, T., Xia, Y., Proud, C. G., Wang, X., Wang, L., Zhao, J., & Gao, L. (2017). A novel role for CRTC2 in hepatic cholesterol synthesis through SREBP‐2. Hepatology, 66(2), 481-497. https://doi.org/10.1002/hep.29206
Liang, Y., Gao, Y., Lin, Q., Luo, F., Wu, W., Lu, Q., & Liu, Y. (2014). A review of the research progress on the bioactive ingredients and physiological activities of rice bran oil. European Food Research and Technology, 238, 169-176. https://doi.org/10.1007/s00217-013-2149-9
Luchetti, F., Crinelli, R., Nasoni, M. G., Benedetti, S., Palma, F., Fraternale, A., & Iuliano, L. (2021). LDL receptors, caveolae and cholesterol in endothelial dysfunction: oxLDLs accomplices or victims? British Journal of Pharmacology, 178(16), 3104-3114. https://doi.org/10.1111/bph.15272
Luo, J., Yang, H., & Song, B.-L. (2020). Mechanisms and regulation of cholesterol homeostasis. Nature Reviews, Molecular Cell Biology, 21(4), 225-245. https://doi.org/10.1038/s41580-019-0190-7
Ma, X., Bai, Y., Liu, K., Han, Y., Zhang, J., Liu, Y., Hou, X., Hao, E., Hou, Y., & Bai, G. (2022). Ursolic acid inhibits the cholesterol biosynthesis and alleviates high fat diet-induced hypercholesterolemia via irreversible inhibition of HMGCS1 in vivo. Phytomedicine, 103, Article 154233. https://doi.org/10.1016/j.phymed.2022.154233
Makhoba, X. H., Viegas, C. Jr., Mosa, R. A., Viegas, F. P. D., & Pooe, O. J. (2020). Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Design, Development and Therapy, 14, 3235-3249. https://doi.org/10.2147/DDDT.S257494
Mancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., Pearson, G. J., Pope, J., & Tashakkor, A. Y. (2016). Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Canadian Journal of Cardiology, 32(7), S35-S65. https://doi.org/10.1016/j.cjca.2016.01.003
Meng, C., Zhou, L., Huang, L., Gu, Q., Du, X., Wang, C., Liu, F., & Xia, C. (2024). Chlorogenic acid regulates the expression of NPC1L1 and HMGCR through PXR and SREBP2 signaling pathways and their interactions with HSP90 to maintain cholesterol homeostasis. Phytomedicine, 123, Article 155271. https://doi.org/10.1016/j.phymed.2023.155271
Miyata, S., Inoue, J., Shimizu, M., & Sato, R. (2015). Xanthohumol improves diet-induced obesity and fatty liver by suppressing sterol regulatory element-binding protein (SREBP) activation. Journal of Biological Chemistry, 290(33), 20565-20579. https://doi.org/10.1074/jbc.M115.656975
Mormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024). Advances in pharmacological approaches for managing hypercholesterolemia: A comprehensive overview of novel treatments. Biomedicines, 12(2), Article 432. https://doi.org/10.3390/biomedicines12020432
Murthy, K. N. C., Monika, P., Jayaprakasha, G. K., & Patil, B. S. (2018). Nanoencapsulation: An advanced nanotechnological approach to enhance the biological efficacy of curcumin. In G. K. Jayaprakasha, B. S. Patil, & G. Gattuso (Eds.). Advances in plant phenolics: From chemistry to human health (pp. 383-405). ACS Publications. https://doi.org/10.1021/bk-2018-1286.ch021
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., Duell, P. B., Brinton, E. A., Pollak, A., Braun, L. T., & Welty, F. K. (2019). Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(2), e38-e81. https://doi.org/10.1161/ATV.0000000000000073
Panahi, Y., Ahmadi, Y., Teymouri, M., Johnston, T. P., & Sahebkar, A. (2018). Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms. Journal of Cellular Physiology, 233(1), 141-152. https://doi.org/10.1002/jcp.25756
Park, J. H., Moon, J. H., Kim, H. J., Kong, M. H., & Oh, Y. H. (2020). Sedentary lifestyle: overview of updated evidence of potential health risks. Korean Journal of Family Medicine, 41(6), 365-373. https://doi.org/10.4082/kjfm.20.0165
Paul, T., & Kumar, K. J. (2024). Standardization of herbal medicines for lifestyle diseases. In A. K. Dhara, & S. C. Mandal (Eds.). Role of herbal medicines (pp. 545-557). Springer. https://doi.org/10.1007/978-981-99-7703-1_27
Peluso, I., Palmery, M., & Serafini, M. (2015). Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination? Current Drug Metabolism, 16(9), 833-846. https://doi.org/10.2174/1389200216666151015113828
Pham, D.-C., Shibu, M. A., Mahalakshmi, B., & Velmurugan, B. K. (2020). Effects of phytochemicals on cellular signaling: reviewing their recent usage approaches. Critical Reviews in Food Science and Nutrition, 60(20), 3522-3546. https://doi.org/10.1080/10408398.2019.1699014
Pirillo, A., & Norata, G. D. (2023). The burden of hypercholesterolemia and ischemic heart disease in an ageing world. Pharmacological Research, 193, Article 106814. https://doi.org/10.1016/j.phrs.2023.106814
Ramkumar, S., Raghunath, A., & Raghunath, S. (2016). Statin therapy: review of safety and potential side effects. Acta Cardiologica Sinica, 32(6), 631-639. https://doi.org/10.6515/acs20160611a
Rezaei-Golmisheh, A., Malekinejad, H., Asri-Rezaei, S., Farshid, A. A., & Akbari, P. (2015). Hawthorn ethanolic extracts with triterpenoids and flavonoids exert hepatoprotective effects and suppress the hypercholesterolemia-induced oxidative stress in rats. Iranian Journal of Basic Medical Sciences, 18(7), 691-699.
Ruuth, M., Äikäs, L., Tigistu-Sahle, F., Käkelä, R., Lindholm, H., Simonen, P., Kovanen, P. T., Gylling, H., & Öörni, K. (2020). Plant stanol esters reduce LDL (low-density lipoprotein) aggregation by altering LDL surface lipids: the blood flow randomized intervention study. Arteriosclerosis, Thrombosis and Vascular Biology, 40(9), 2310-2321. https://doi.org/10.1161/ATVBAHA.120.314329
Safari-Alighiarloo, N., Taghizadeh, M., Rezaei-Tavirani, M., Goliaei, B., & Peyvandi, A. A. (2014). Protein-protein interaction networks (PPI) and complex diseases. Gastroenterology and Hepatology from Bed to Bench, 7(1), 17-31.
Saklayen, M. G. (2018). The global epidemic of the metabolic syndrome. Current Hypertension Reports, 20(2), Article 12. https://doi.org/10.1007/s11906-018-0812-z
Shi, Z., & Han, S. (2025). Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins. Heliyon, 11(1), Article e41629. https://doi.org/10.1016/j.heliyon.2025.e41629
Shimano, H., & Sato, R. (2017). SREBP-regulated lipid metabolism: convergent physiology-divergent pathophysiology. Nature Reviews Endocrinology, 13(12), 710-730. https://doi.org/10.1038/nrendo.2017.91
Srivastava, S., & Misra, A. (2018). Quality control of herbal drugs: Advancements and challenges. In B. Singh, & K. Peter (Eds.). New age herbals: resource, quality and pharmacognosy (pp. 189-209). Springer. https://doi.org/10.1007/978-981-10-8291-7_10
Sut, S., & Dall'Acqua, S. (2023). Food-derived nutraceuticals for hypercholesterolemia management, mode of action and active ingredients. Food Bioscience, 54, Article 102866. https://doi.org/10.1016/j.fbio.2023.102866
Svatikova, A., & Kopecky, S. L. (2017). Cholesterol management in the era of PCSK9 inhibitors. Current Cardiology Reports, 19, Article 83. https://doi.org/10.1007/s11886-017-0891-5
Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N. T., Legeay, M., Fang, T., Bork, P., Jensen, L., & von Merring, C. (2021). The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Research, 49(D1), D605-D612. https://doi.org/10.1093/nar/gkab835
Tavori, H., Rashid, S., & Fazio, S. (2015). On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis, 238(2), 264-270. https://doi.org/10.1016/j.atherosclerosis.2014.12.017
Trautwein, E. A., Vermeer, M. A., Hiemstra, H., & Ras, R. T. (2018). LDL-cholesterol lowering of plant sterols and stanols-which factors influence their efficacy? Nutrients, 10(9), Article 1262. https://doi.org/10.3390/nu10091262
Upadhyay, R. K. (2023). High cholesterol disorders, myocardial infarction and its therapeutics. World Journal of Cardiovascular Diseases, 13(8), 433-469. https://doi.org/10.4236/wjcd.2023.138040
Upadhyay, S., & Dixit, M. (2015). Role of polyphenols and other phytochemicals on molecular signaling. Oxidative Medicine and Cellular Longevity, 2015(1), Article 504253. https://doi.org/10.1155/2015/504253
Vallianou, I., & Hadzopoulou-Cladaras, M. (2016). Camphene, a plant derived monoterpene, exerts its hypolipidemic action by affecting SREBP-1 and MTP expression. PLoS One, 11(1), Article e0147117. https://doi.org/10.1371/journal.pone.0147117
Vekic, J., Zeljkovic, A., Stefanovic, A., Bogavac-Stanojevic, N., Ilias, I., Silva-Nunes, J., Stoian, A. P., Janez, A., & Rizzo, M. (2022). Novel pharmaceutical and nutraceutical-based approaches for cardiovascular diseases prevention targeting atherogenic small dense LDL. Pharmaceutics, 14(4), Article 825. https://doi.org/10.3390/pharmaceutics14040825
Vučević, D., Đorđević, D., Stanojević, M., Jorgačević, B., Đorović, D., Radak, Đ., & Radosavljević, T. (2016). Hypercholesterolemias: Pathogenesis and pathophysiological implications. Medicinska Istraživanja, 50(2), 30-43. https://doi.org/10.5937/MedIst1602030V
Wang, H. H., Liu, M., Portincasa, P., & Wang, D. Q.-H. (2020). Recent advances in the critical role of the sterol efflux transporters ABCG5/G8 in health and disease. Advances in Experimental Medicine and Biology, 1276, 105-136. https://doi.org/10.1007/978-981-15-6082-8_8
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019). Statin toxicity: mechanistic insights and clinical implications. Circulation Research, 124(2), 328-350. https://doi.org/10.1161/CIRCRESAHA.118.312782
Xu, J., Wang, T., Shu, H., Shi, S., Tao, L., & Li, J.-J. (2023). Insight into the role of PCSK9 in glucose metabolism. Clinica Chimica Acta, 547, Article 117444. https://doi.org/10.1016/j.cca.2023.117444
Yamanashi, Y., Takada, T., & Suzuki, H. (2018). Associations between lifestyle-related diseases and transporters involved in intestinal absorption and biliary excretion of cholesterol. Biological and Pharmaceutical Bulletin, 41(1), 1-10. https://doi.org/10.1248/bpb.b17-00690
Zhang, S., Ren, X., Zhang, B., Lan, T., & Liu, B. (2024). A systematic review of statins for the treatment of nonalcoholic steatohepatitis: safety, efficacy, and mechanism of action. Molecules, 29(8), Article 1859. https://doi.org/10.3390/molecules29081859
Zhao, W., Xu, S., & Weng, J. (2023). ASGR1: an emerging therapeutic target in hypercholesterolemia. Signal Transduction and Targeted Therapy, 8(1), Article 43. https://doi.org/10.1038/s41392-023-01319-5
Zhao, Y., Liu, J., Hao, W., He, Z., Zhu, H., Liang, N., Ma, K. Y., He, W.-S., Yang, Y, & Chen, Z.-Y. (2018). Plasma cholesterol-lowering activity of piperine is mediated by inhibition on cholesterol absorption via down-regulation of intestinal ACAT2 and MTP. Journal of Functional Foods, 49, 465-471. https://doi.org/10.1016/j.jff.2018.09.014
Zheng, Z., Zhou, Y., Zhang, X., Myat, P., Xie, Z., Lu, C., Pang, T., Xue, B., Xu, D., Chen, Y., Chen, X., Li, H., & Xu, X. (2016). Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation. Biochemical Pharmacology, 122, 42-61. https://doi.org/10.1016/j.bcp.2016.10.016
